Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0332 | 1 | 1 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0332 | 1 | 0.5 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Echinococcus granulosus | mitogen activated protein kinase | 0.0332 | 1 | 1 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0332 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0332 | 1 | 1 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Chlamydia trachomatis | enoyl-acyl-carrier protein reductase | 0.0181 | 0.5117 | 0.5 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0181 | 0.5117 | 0.5 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Trichomonas vaginalis | CMGC family protein kinase | 0.0332 | 1 | 1 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0181 | 0.5117 | 0.5 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0181 | 0.5117 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0332 | 1 | 1 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0332 | 1 | 1 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Trichomonas vaginalis | CMGC family protein kinase | 0.0332 | 1 | 1 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Trypanosoma brucei | protein kinase, putative | 0.0332 | 1 | 0.5 |
Onchocerca volvulus | Neuropeptide F receptor homolog | 0.0023 | 0 | 0.5 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0332 | 1 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0332 | 1 | 1 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0332 | 1 | 0.5 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0181 | 0.5117 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0332 | 1 | 0.5 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0181 | 0.5117 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0332 | 1 | 0.5 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0332 | 1 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0332 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0332 | 1 | 1 |
Onchocerca volvulus | Dopamine\/Ecdysteroid receptor homolog | 0.0023 | 0 | 0.5 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0181 | 0.5117 | 0.5 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0332 | 1 | 1 |
Onchocerca volvulus | 0.0023 | 0 | 0.5 | |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0332 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | Neuroprotective activity in mouse middle cerebral artery occlusion model assessed as reduction in activated microglial cells in medial periphery of cortical infarct area at 30 mg/kg, ip administered 1 hr prior to onset of ischemia measured after 24 hrs by Iba-1 staining-based microscopic analysis | ChEMBL. | 24456901 | |
Activity (functional) | Neuroprotective activity in ip dosed mouse middle cerebral artery occlusion model assessed as reduction in infarction volume administered 1 hr prior to onset of ischemia measured after 24 hrs by TTC staining-based microscopic analysis | ChEMBL. | 24456901 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.